SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?

V Quagliariello, A Bonelli, A Caronna, M C Lombari, G Conforti, M Libutti, R V Iaffaioli, M Berretta, G Botti, N Maurea

Research output: Contribution to journalArticlepeer-review

Abstract

NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.

Original languageEnglish
Pages (from-to)9169-9171
Number of pages3
JournalEuropean Review for Medical and Pharmacological Sciences
Volume24
Issue number17
DOIs
Publication statusPublished - Sep 2020

Keywords

  • Betacoronavirus/isolation & purification
  • Cardiovascular Diseases/prevention & control
  • Clinical Trials as Topic
  • Coronavirus Infections/diagnosis
  • Cytokines/metabolism
  • Humans
  • Inflammasomes/metabolism
  • Myocarditis/prevention & control
  • NLR Family, Pyrin Domain-Containing 3 Protein/antagonists & inhibitors
  • Nitriles/therapeutic use
  • Pandemics
  • Pneumonia, Viral/diagnosis
  • Prognosis
  • Venous Thromboembolism/prevention & control
  • ortho-Aminobenzoates/therapeutic use

Fingerprint Dive into the research topics of 'SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?'. Together they form a unique fingerprint.

Cite this